/
We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate and naturally occurring Public Health Threats ( PHTs ). Our solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing ( CDMO ) services portfolio.
13.47% operating margin is respectable but not wide. ROIC at 6.17%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 28.8% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$677M
▼ -28.8% YoY
Net Income (TTM)
-$9M
▲ +127.6% YoY
Op. Margin
8.97%
▲ +23.9pp YoY
ROIC
4.15%
▲ +11.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$135M
▲ +338.0% YoY
Op. Cash Flow (TTM)
$148M
▲ +190.6% YoY
Net Debt
$424M
Cash & Equiv.
$160M
5Y CAGR: -14.0%
5Y CAGR: -16.9%
Continue Research